Clinical trials: PET/CT
Childhood Cancer
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
This pilot clinical trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI) works compared to PET/computed tomography (CT) in diagnosing younger patients with cancer.
- Trial name
- NCT02287636
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Transthyretin Amyloidosis
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since…
- Trial name
- NCT05635045
- Testing
- I 124-Evuzamitide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
Cholestasis, Primary Sclerosing Cholangitis
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
We wish to develop a protocol for PET/CT examination of humans using the bile acid tracer 11C-cholylsarcosine. This is done by a series of PET/CT examinations of healthy humans and patients with cholestatic disorders.
- Conditions
- Cholestasis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- NCT01879735
- Testing
- 11C-CSar, ICG
- Where
- Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Haemodialysis-induced Symptom
Cerebral Blood Flow During Hemodialysis
The purpose of this study is to evaluate the effect of the hemodialysis procedure on cerebral blood flow (CBF) in elderly maintenance hemodialysis (HD) patients.
- Trial name
- NCT02272985
- Testing
- [15O]H2O PET-CT scan, NIRS (Invos)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Coronary Artery Disease, Carotid Artery Disease
Assessment Of Vascular Health After Niacin Therapy (AVANT)
This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic…
- Conditions
- Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
- Trial name
- AVANT (NCT02003638)
- Testing
- Niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer…
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Trial name
- NCT02274038
- Testing
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Pulmonary Nodule
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before and after steroid therapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00906503
- Testing
- dexamethasone, PET/Computed Tomography (CT), fludeoxyglucose (18F)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Indication for a PET CT Exam
Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and Components
The PET/MR device components and accessories are under development in order to optimize, validate and improve the design including improving the quality of images.
- Trial name
- NCT01992354
- Testing
- PET MR Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Cervical Cancer
Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis[N4-methylthiosemicarbazone] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment.
- Trial name
- ACRIN6682 (NCT00794339)
- Testing
- 64Cu-ATSM, FDG
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- American College of Radiology
Acute Myeloid Leukemia
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia.
- Trial name
- NCT02392429
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate cancer (PC) remains the most-common non-cutaneous cancer diagnosed in American males, accounting for an estimated 174,560 estimated new cases and 31,620 estimated deaths in 2019.
- Trial name
- NCT02624518
- Testing
- 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Andrei Iagaru
Squamous Cell Carcinoma of the Head and Neck
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
The results of previous studies suggest further development of [18F]EF5 as a PET tracer for imaging hypoxia. This is a non-randomized prospective study to obtain information on reproducibility of [18F]EF5 intratumor distribution…
- Trial name
- NCT01774760
- Testing
- 18F-EF5, Pretreatment PET/CT-scan (performed two times)
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- Turku University Hospital
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Hypermetabolic Lymphadenopathy Mediastinum Lower, Posterior and Middle, Detected by PET-CT With 18F-FDG (PET)
Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy
Impact of screening nodes mediastinal by PET, at different times of the management of cancer disease, remain unclear. Benefits of combined PET and puncture with echoendoscopy for the diagnosis subsequent therapeutic management…
- Trial name
- APOGEE (NCT01892501)
- Testing
- Guided punction of mediastinal lymphadenopathy by echoendoscopy, PET scan
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Institut Bergonié
Prostate Adenocarcinoma
Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.
- Trial name
- BoneMetPETCT (NCT03496844)
- Testing
- F-18 fluciclovine-PET/CT scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Brain Cancer
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing.
- Trial name
- NCT01604512
- Testing
- MRI perfusion and PET/CT scans
- Where
- 6 sites in United States
- Volunteers
- 148 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins